We have a balanced, diverse and experienced Board. Dr. Pamela Kirby joined the Board on 3 September 2013 and brought to us substantial senior management and non-executive director experience in UK, European and US business development, especially in the healthcare sector. The ‘Women on Boards Davies Review Annual Report 2014’ lists DCC as one of only 17 FTSE 250 companies with three or more women on their boards.
Earlier in 2014, David Byrne, the Deputy Chairman and Senior Independent Director, and I facilitated an internal evaluation of the effectiveness of the DCC Board, which covered individual and collective effectiveness and efficiency and dealt with Board committees as well as the Board as a whole. The results of actions implemented following recent evaluations are showing that the significantly greater diversity of experience and expertise brought to the table as a result of new Board appointments over the past six years is paying dividends, in terms of the quality of Board discussion and its decision-making. As was the case last year, the 2014 review generated a number of worthwhile suggestions for improvement in the way we operate, which we have agreed to address over the balance of this financial year. The comparable list from last year’s evaluation was substantially implemented. Next year, we will again commission a leading independent Board evaluation firm to facilitate the evaluation, as we did in 2012, in accordance with the Code provision.
The non-executive Directors made a number of site visits to Group subsidiaries during the year ended March 2014, as part of their ongoing training and development.